Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ïåäèàòðèÿ

Ïåäèàòðèÿ Ôîðóìû: Âàêöèíîïðîôèëàêòèêà, Ôîðóì äëÿ âðà÷åé ïåäèàòðîâ, ×àñòî çàäàâàåìûå âîïðîñû, Ïñèõîìîòîðíîå è ðå÷åâîå ðàçâèòèå äåòåé, Äåòñêî-ðîäèòåëüñêèå îòíîøåíèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 08.02.2023, 19:10
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,396
Ïîáëàãîäàðèëè 33,237 ðàç(à) çà 31,586 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
âîò êëèíè÷åñêèå íàõîäêè ó äåòåé ñ ïîðàæåíèåì ðòà ãåðïåñîì -
185 cases were considered as PHGS and were included for analysis. Fever was present in 99.5%. The mean duration of fever was 5.11 days (±2.24) with the longest being 17 days. Common oral manifestations included oral ulcers (84.3%), which equally resided in the anterior and posterior part of the oral cavity (65.4% vs. 63.2%), gum swelling and/or bleeding (67.6%), and exudate coated tonsils (16.8%). Leukocytosis (WBC count > 15,000/uL3) was noted in 52 patients (28.1%) and a serum C-reactive protein level > 40 mg/L in 55 patients (29.7%). Fixty-five patients (35%) were diagnosed with PHGS on admission and were significantly more likely to have ulcers over the anterior oral cavity (76.1% vs. 26.7%) and gum swelling/bleeding (76.2% vs. 7.5%, p-value all < 0.001) on admission and were significantly less likely to receive antibiotic treatment (16.9 vs. 36.7%, p-value < 0.01) than others.
---
BMC Infect Dis. 2020 Oct 20;20(1):782.
Clinical features of gingivostomatitis due to primary infection of herpes simplex virus in children
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 08.02.2023, 19:14
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,396
Ïîáëàãîäàðèëè 33,237 ðàç(à) çà 31,586 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ëèõîðàäêà â 100% è äî 17 äíåé; ëåéêîöèòîç áîëåå 15 êàê ó âàøåãî ðåáåíêà ó êàæäîãî 3-4 ðåáåíêà; öðá áîëåå 40 ó êàæäîãî òðåòüåãî, åñëè ãåðïåñ áûë îáíàðóæåí ñðàçó, òî ðèñê ïîëó÷åíèÿ íåíóæíûõ ÀÁ ïàäàë äî êàæäîìó 7-ìó âìåñòî êàæäîìó òðåòüåìó
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 10.02.2023, 11:55
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Ñåãîäíÿ 15é äåíü áîëåçíè.

Äâà äíÿ íàçàä íî÷üþ ðåáåíîê ïîæàëîâàëñÿ íà øóì â óõå. ß ïîòðîãàëà, ïîñìîòðåëà, ñêàçàëà ÷òî ïðîøëî ê óòðó. Ïîçàâ÷åðà è â÷åðà íà ìîè âîïðîñû ïðî øóì è áîëü îòâå÷àëà, ÷òî âñå íîðìàëüíî.
Ñåãîäíÿ íî÷üþ ñòàëà âûòåêàòü æèäêîñòü (æåëòîâàòàÿ ìîæåò áûòü ÷óòü ðîçîâàòàÿ, ò.ê. ìíå ïîêàçàëîñü íà ìàéêå áåëîé ÷òî ïÿòíî áóäòî êðàñíîâàòîå). Óæå ïîëäåíü, æèäêîñòü ïîäòåêàåò ÷àñà 3 óæå êàê ïðîñíóëàñü.
 íî÷ü êîãäà ïåðâûé ðàç æàëîáû íà óõî ïîÿâèëèñü è ñåãîäíÿ íî÷üþ, çàêàïûâàëè Íàçèâèí.

Îêàçûâàåòñÿ, áûëè îùóùåíèå êàêèå-òî â óõå ýòè äâà äíÿ, íî ðåáåíîê íå ãîâîðèë.

Òåìïåðàòóðà, â ñâÿçè ñ áîëåçíüþ, ñåãîäíÿ 15é äåíü, ñåãîäíÿ óòðîì 37,5.
Íî÷üþ ÷àñà íà 4 ïîäíèìàëàñü 38.5.
Â÷åðà áûëî äî 38.9 äíåì, ñáèâàëà. Ðåáåíîê áûë ïîæèâåå ÷åì äî ýòîãî, è íà÷àë íåìíîãî åñòü.

Ãîðëî, êàê ìíå êàæåòñÿ ñòàëî áëåäíåå. Ñòàðûå ÿçâû ïðîøëè. Íî ìíå â÷åðà ïîêàçàëîñü ÷òî ðÿäîì ïîÿâëÿþòñÿ 2 íîâûõ, íî ïîêà íå óâåðåíà.

Ðåçóëüòàò ÍÀ ÃÅÐÏÅÑ ïðèøåë, ñäàííûé 2 äíÿ íàçàä, anti-HSV (1 è 2 òèïà) IgM - îòðèöàòåëüíî

Ñèäèì ê Ëîðó.

1. Ðàçðûâ áàðàáàííîé ïåðåïîíêè ? Èëè ÷òî-òî äðóãîå? Îñëîæíåíèÿ îò ãåðïàíãèíû (íå ïîäòâåðæäåííîé)?
2. Êàê ëå÷èòü? Àíòèáèîòèê Àìîêñèöèëëèí? Êàêàÿ äîçèðîâêà (âåñ 21.5 êã , ðîñò 130 , âîçðàñò 8 ëåò), ñêîëüêî äíåé?
3. Êàêèå ìåðû è ëåêàðñòâà íåîáõîäèìû?
4. Äîïîëíèòåëüíûå îáñëåäîâàíèÿ?
5. Åñëè ðàçðûâ ïåðåïîíêè, êàïëè â óõî è ñîñóäîñóæèâàþùèå â íîñ íåëüçÿ æå?
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 10.02.2023, 12:38
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Ìîæåò ëè ýòî áûòü ìåíèíãèò?

Ñêîëüêî âðåìåíè ìîæåò âûòåêàòü èç óõà æèäêîñòü?

Íà ÷òî îáðàùàòü âíèìàíèå?

Åù¸, âäðóã ýòî èìååò çíà÷åíèå, ãëàíäû ñî ñòîðîíû áîëüíîãî óõà, ïàðó äíåé óæå áóäòî ðûõëàÿ ñòàëà, áóäòî â íåé ïîÿâèëèñü äûðî÷êè, îòâåðñòèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 10.02.2023, 12:45
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,881
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,334 ðàç(à) çà 8,908 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ËÎÐ ñìîòðåë.Ïåðôîðàöèÿ áàðàáàíîé ïåðåïîíêè -íåðåäêîå ÿâëåíèå ïðè îòèòå(ñàìî÷óñòâèå óëó÷øàåòñÿ îáû÷íî).Àìîêñèöèëèíðåêîìåíäóþò ïðè îòèòå â äîçèðîâêå 75-80 ìã/êã â ñóòêå íå áîëåå 1500 â äåíü, ò.å ðåáåíêó âåñîì 21 êã â äîçå 750 ìã* 2/äåíü èëè 500*3 /äåíü.Êëèíèêó ìåíèíãèòà Âû íå îïèñûâàåòå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 10.02.2023, 14:02
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Âûøëè îò Ëîðà.
Ïî ãîðëó íè÷åãî íå ñêàçàëà è ïî ïåðâè÷íîìó äèàãíîçó. Ñêàçàëà âûñûïàíèé íå âèäèò, ãîðëî êðàñíîå åùå.

Ïî óõó - ãíîéíûé îòèò.

Âûïèñàëà:
1. Âèëüïðàôåí 1000ìã. ïî 1/2 òàáë. × 2 ð. Â äåíü 7 äíåé
2. 3% ðàñòâîð ïåðåêèñè âîäîðîäà â áîëüíîå óõî êàïàòü îáèëüíî è âàòîé ñêðó÷åííîé ñîáèðàòü èç óõà ïîñëå ïîÿâëåíèÿ ïóçûðåé (èëè äèîêñèäèí , åñëè ÿ ïðàâèëüíî çàïîìíèëà, åñëè åñòü äîìà ñïðàøèâàëà ,ó íàñ íåò)
3. Îòîôà ïî 3 êàï. × 3 ðàçà â äåíü 7 äíåé , Â îáà óõà.

Íà ìîé âîïðîñ ÷òî ïðè ðàçðûâå ïåðåïîíêè êàïàòü íåëüçÿ â óõî, îòâåòèëà ÷òî íàîáîðîò áåç êàïåëü ñëóõ ïîòåðÿòü ìîæåò.

Íà âîïðîñ , ïî÷åìó íå Àìîêñèöèëèí (1ãî ðÿäà àíòèáèîòèê), ñêàçàëà ÷òî ïî å¸ ïðàêòèêå îí íå äåéñòâóåò.

Óâàæàåìûå äîêòîðà , ÷òî æå ìíå äàâàòü ðåáåíêó è êàêèå äîçû?
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 10.02.2023, 14:05
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Öèòàòà:
Ñîîáùåíèå îò eduardshraibman Ïîñìîòðåòü ñîîáùåíèå
ËÎÐ ñìîòðåë.Ïåðôîðàöèÿ áàðàáàíîé ïåðåïîíêè -íåðåäêîå ÿâëåíèå ïðè îòèòå(ñàìî÷óñòâèå óëó÷øàåòñÿ îáû÷íî).Àìîêñèöèëèíðåêîìåíäóþò ïðè îòèòå â äîçèðîâêå 75-80 ìã/êã â ñóòêå íå áîëåå 1500 â äåíü, ò.å ðåáåíêó âåñîì 21 êã â äîçå 750 ìã* 2/äåíü èëè 500*3 /äåíü.Êëèíèêó ìåíèíãèòà Âû íå îïèñûâàåòå.
Ñïàñèáî çà îòâåò!
Âûøå îïèñàëà íàçíà÷åíèÿ Ëîðà. Òîëüêî óâèäåëà âàø îòâåò.

Ïðîêîììåíòèðóéòå ïîæàëóéñòà å¸ íàçíà÷åíèÿ.
×òî â èòîãå äàâàòü ðåáåíêó? È àíòèáèîòèê è êàïëè åñëè íàäî

Îíà ñêàçàëà âî âòîðíèê ê íåé ïîêàçàòüñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 10.02.2023, 14:59
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Åù¸ óòî÷íþ, óõî ëîð íå ñìîòðåëà, ñðàçó âàòîé çàòêíóëî, ò.ê. òå÷åò ïîñòîÿííî èç íåãî.

Ñìîòðåëà òîëüêî íîñ è ãîðëî, ñïðàøèâàëà åñòü ëè íàñìîðê.

Åñòü êàøåëü èíîãäà âëàæíûé, íîñ ñîâñåì ÷óòîê îòñìàðêèâàåòñÿ, ïî çàäíåé ñòåíêå ñòåêàåò.

Ïðè÷èíà îòèòà - ðåáåíîê ïûòàëñÿ ñèëüíî âûñìîðêàòüñÿ? È ïîïàëî â óõî èíôåêöèÿ?

Æèäêîñòü èç óõà - ýòî æå 100% ðàçðûâ ïåðåïîíêè?
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 10.02.2023, 17:43
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Íà÷àëè ïèòü Âèëüïðàôåí.


1. Ïî êàïëÿì Îòîôà è ïåðåêèñè âîäîðîäà âîïðîñ îòêðûò.

2. Ìîæåò íàäî ÷òî-òî äðóãîå âìåñòî ýòèõ êàïåëü?

3. Ðåáåíîê âûïëþíóë ðàñòâîð Âèëüïðîôåíà, äóìàþ ÷àñòè÷íî. ×òî äåëàòü â òàêèõ ñëó÷àÿõ?
ß äàëà íîâóþ äîçó. Íå óâåðåííà, ÷òî òàê ïðàâèëüíî.

4. Ìîæíî ëè ïðèêðûâàòü óõî âàòîé, ò.ê. ïîñòîÿííî òå÷¸ò?
Êàê ñïàòü? Íàäî ëè âûáèðàòü ïîëîæåíèå ãîëîâû?
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 10.02.2023, 18:40
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,396
Ïîáëàãîäàðèëè 33,237 ðàç(à) çà 31,586 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
åñëè âíóòðü àíòèáèîòèê äàâàòü íå ñìîæåòå, òî ìåñòíûå êàïëè ñ îôëîêñàöèíîì - èíäèéñêèé äàíöèë â Ðîññèè - ëó÷øå ñèñòåìíûõ àíòèáèîòèêîâ

Eleven clinical trials (9 randomized and 2 nonrandomized) enrolling 1,484 adults and children were finally included in the analysis....0.3% ofloxacin otic solution is better than other otic antibiotic drops and other oral antibiotics in terms of overall cure rate and resolution of secondary outcome parameters.
ORL J Otorhinolaryngol Relat Spec. 2003 Mar-Apr;65(2):106-16.
A systematic review of the effectiveness of ofloxaxin otic solution for the treatment of suppurative otitis media.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 10.02.2023, 18:44
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
×åðåç ÷àñ ïîñëå àíòèáèîòèêà ðåáåíêà ñèëüíî âûðâàëî.
×òî äåëàòü???

Äàâàòü ëè åù¸ äîçó?
Ìîæåò ëè ýòî áûòü íåïåðåíîñèìîñòü?
×òî âöåëîì äåëàòü?
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 10.02.2023, 18:46
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
åñëè âíóòðü àíòèáèîòèê äàâàòü íå ñìîæåòå, òî ìåñòíûå êàïëè ñ îôëîêñàöèíîì - èíäèéñêèé äàíöèë â Ðîññèè - ëó÷øå ñèñòåìíûõ àíòèáèîòèêîâ

Eleven clinical trials (9 randomized and 2 nonrandomized) enrolling 1,484 adults and children were finally included in the analysis....0.3% ofloxacin otic solution is better than other otic antibiotic drops and other oral antibiotics in terms of overall cure rate and resolution of secondary outcome parameters.
ORL J Otorhinolaryngol Relat Spec. 2003 Mar-Apr;65(2):106-16.
A systematic review of the effectiveness of ofloxaxin otic solution for the treatment of suppurative otitis media.
Âîò êàê ðàç òîëüêî ÷òî âûðâàëî ñèëüíî.
Ýòî çíà÷èò ÷òî àíòèáèîòèê íå ïîäõîäèò?
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 10.02.2023, 18:50
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,396
Ïîáëàãîäàðèëè 33,237 ðàç(à) çà 31,586 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ìíå åòî íåèçâåñòíî, èíîãäà ðåáåíêà ðâåò íà âêóñ èëè íàïîëíèòåëè ëåêàðñòâà, âñå ÷òî çíàë - íàïèñàë âûøå, êàê âû ïîñòóïèòå - âàøå ïðàâî;

íå çíàþ, ÷òî âû òàì äà¸òå èç ÀÁ, ìíå êîììåð÷. íàçâàíèÿ â ðô íåâåäîìû, íî âîò ëå÷åíèå îòèòà ó äåòåé àóãìåíòèíîì (àìîêñèêëàâîì) ïðîòèâ êàïåëü:

èçëå÷åíèå áûëî â 76%, óäàëåíèå áàêòåðèé â 96 è ïîá. äåéñòâèå ó êàæäîãî 15-ãî; íà àìîêñîêëàâå èçëå÷èâàëîñü 70% è ó êàæäîãî òðåòüåãî - ïîá. äåéñòâèå

Overall cure rate for clinically evaluable subjects was 76% with OFLX (n = 140) and 69% with AUG (n = 146; P = 0.169).

OFLX had a greater overall pathogen eradication rate (96% vs. 67%; P<0.001).

Treatment-related adverse event rates were 31% for AUG and 6% for OFLX (P<0.001).
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 10.02.2023, 19:13
Luck1 Luck1 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 02.02.2023
Ãîðîä: Samara
Ñîîáùåíèé: 19
Ñêàçàë(à) ñïàñèáî: 8
Luck1 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
ìíå åòî íåèçâåñòíî, èíîãäà ðåáåíêà ðâåò íà âêóñ èëè íàïîëíèòåëè ëåêàðñòâà, âñå ÷òî çíàë - íàïèñàë âûøå, êàê âû ïîñòóïèòå - âàøå ïðàâî;

íå çíàþ, ÷òî âû òàì äà¸òå èç ÀÁ, ìíå êîììåð÷. íàçâàíèÿ â ðô íåâåäîìû, íî âîò ëå÷åíèå îòèòà ó äåòåé àóãìåíòèíîì (àìîêñèêëàâîì) ïðîòèâ êàïåëü:

[).
Ýòî àíòèáèîòèê - ìàêðîëèä Äæîçàìèöèí

Ìîæíî ïîïðîáûâàòü åù¸ ðàç åãî äàòü ñåé÷àñ?
Ïåðåäîçèðîâêè íå áóäåò?

ß îïàñàþñü ÷òî ïåðâè÷íàÿ áîëåçíü, åñëè âäðóã ýòî íå ãåðïàíãèíà, íåäîëå÷åííîé îñòàíåòñÿ, ðàç óæ ïðèøëîñü âñ¸-ðàâíî àíòèáèîòèê ïðèìåíÿòü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 10.02.2023, 19:22
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,396
Ïîáëàãîäàðèëè 33,237 ðàç(à) çà 31,586 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íåò ýòîãî ïðåïàðàòà ñðåäè ðåêîìåíäóåìûõ ìàêðîëèäîâ äëÿ äåòåé ñ îòèòîì - èëè àçèòðî- èëè êëàðèòðî-, êîãäà àëëåðãèÿ íà ïåíèöèëëèíû; ðâîòà íà ëåêàðñòâî - ãîâîðèò îá îòñóòñòâèè ýôôåêòà è âîçì. ïîá. äåéñòâèè; ïûòàòüñÿ äàâàòü åãî ïîâòîðíî - íàïîìèíàåò îòäàë¸ííî äàâàòü òóìàêè ðåáåíêó, ÷òîáû ó íåãî ïåðåñòàëà áîëåòü ãîëîâà; âû âèäèòå òàáëèöó ïî ññûëêå?

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 00:38.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.